A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Am J Rhinol Allergy. 2021 Nov;35(6):861-870. doi: 10.1177/19458924211009429. Epub 2021 Apr 11.
Am J Rhinol Allergy. 2021.
PMID: 33840229
Clinical Trial.